JCO commentary reexamines routine corticosteroid use in glioblastoma
For more than half a century, corticosteroids have sat at the bedside of patients with glioblastoma as if their role were settled. They are used to blunt vasogenic edema, ease headache, reduce focal deficits, and stabilize neurologic function when mass effect becomes clinically urgent. Yet the title of this Journal of Clinical Oncology commentary signals a deliberate challenge to that habit: corticosteroids in glioblastoma deserve reconsideration, not automatic repetition.
The argument matters because glioblastoma care is built around tradeoffs. Every intervention is measured against neurologic preservation, quality of life, treatment tolerance, and the narrow margin between symptom relief and harm. Steroids can rapidly improve intracranial pressure-related symptoms, but their benefits come with a familiar burden of adverse effects that often accumulates across repeated dosing or prolonged exposure. In a disease already defined by neurologic decline, immune dysfunction, and treatment toxicity, even a routine supportive drug can shape the entire clinical course.
A one-sentence reality anchors the discussion: the same medication that can calm cerebral edema can also complicate the biology and day-to-day management of brain tumor care.
Why a 65-year practice is no longer easy to defend as reflex
The title’s phrasing suggests more than a minor therapeutic adjustment. It points to a long-standing practice that may have outlived the evidence base supporting its broad use. In neuro-oncology, steroids are often treated as default therapy rather than as a time-limited bridge to a specific goal. That pattern persists because the bedside effect is immediate and visible, while the downstream costs are more diffuse: proximal myopathy, hyperglycemia, mood changes, insomnia, infection risk, skin fragility, and the functional erosion that can follow prolonged exposure.
Glioblastoma intensifies the problem. Patients frequently receive surgery, radiation, temozolomide, and other interventions that already strain marrow reserve, energy levels, appetite, and cognition. Adding chronic corticosteroids can blur the clinical picture, making it harder to separate tumor progression from treatment toxicity or steroid-induced decline. A patient who looks weaker, more irritable, or cognitively slowed may be suffering from the disease, the treatment, or both.
The biology also pushes against complacency. Corticosteroids are potent anti-inflammatory agents, but glioblastoma is not a simple inflammatory disorder. Its microenvironment, blood-brain barrier disruption, edema dynamics, and interaction with immune function create a setting in which suppressing symptoms does not necessarily mean changing the disease in a favorable direction. If anything, the immune effects of steroids can be particularly relevant in a tumor type where preservation of antitumor immunity remains an active concern.
Symptom relief does not equal therapeutic neutrality
Clinical convenience has always been a reason steroids remain entrenched in neuro-oncology. They can work quickly, and that speed matters when edema threatens speech, gait, vision, or consciousness. No serious clinician would dismiss that benefit. The problem is that a medication used for rescue can gradually become part of the background regimen, and the threshold for discontinuation often drifts upward once a patient and care team become accustomed to its short-term clarity.
That drift has consequences. Steroid exposure can raise glucose levels, worsen muscle wasting, and compound fatigue, all of which matter in a population already vulnerable to deconditioning. Neuropsychiatric effects can be especially destabilizing for patients and caregivers trying to navigate a life-limiting diagnosis. Even when the tumor itself is unchanged, the patient’s daily function can worsen because the drug meant to help has become a source of cumulative harm.
The commentary’s title also invites a more disciplined question: when should corticosteroids be used, at what dose, and for how long? Those are not minor details. They define whether the medication remains a targeted intervention or becomes an open-ended liability. In glioblastoma, the goal should be the lowest effective dose for the shortest feasible duration, with frequent reassessment of whether the original indication still exists.
Supportive care in glioblastoma needs stricter boundaries
Any reevaluation of steroid use must respect the real bedside scenarios in which they remain useful. Severe edema, impending herniation, and acute neurologic deterioration still call for prompt action. The argument is not for abolishing corticosteroids from glioblastoma care. It is for resisting their habitual extension beyond the moment when they are truly needed.
That approach fits the broader direction of modern oncology, which increasingly asks whether long-standing supportive practices improve outcomes or simply persist because they are familiar. In glioblastoma, this question carries unusual weight because patients face both a highly aggressive tumor and a narrow therapeutic window. A supportive drug that worsens weakness, sleep, glucose control, or infection susceptibility can indirectly undermine the delivery of definitive therapy and the patient’s ability to tolerate it.
The article’s framing also suggests a call for more careful evidence generation. If corticosteroids are to remain central to glioblastoma management, the field needs clearer boundaries around indications, dosing strategies, taper schedules, and patient selection. Clinicians need evidence that distinguishes temporary symptom control from meaningful net benefit across the full trajectory of care. Without that clarity, practice remains driven by habit more than precision.
The unresolved issue is not whether steroids work, but when they still help enough
That question sits at the center of this commentary. The urgent benefit of edema control is undisputed, yet the cumulative biological and functional costs can be substantial, especially when treatment becomes prolonged. A 65-year practice does not deserve loyalty simply because it is familiar. In glioblastoma, familiarity can obscure harm.
The article does not provide a new trial, dose comparison, or quantified safety signal in the accessible material, so the most defensible reading is conceptual rather than numerical. Even so, the clinical message is direct: corticosteroids should be treated as a deliberate, revisited intervention in glioblastoma, not as a reflexive default. The field still needs better prospective data on the balance between neurologic relief and longer-term toxicity, particularly in patients whose symptoms fluctuate during multimodal cancer therapy.
Until those data are stronger, the practical challenge for neuro-oncology is restraint. Use steroids when edema demands it, taper when the neurologic indication fades, and avoid letting a short-term bridge become a chronic burden.